ENDPOINTS

Servier licenses Black Diamond’s RAS- and RAF-targeted drug

Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources on developing a next-generation lung cancer therapy. Servier will pay ...

Mar 19, 2025 - 19:37
 0
Servier licenses Black Diamond’s RAS- and RAF-targeted drug
Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources on developing a next-generation lung cancer therapy. Servier will pay ...
Read More

Tags:

Previous Article

Watch enormous deep-sea spiders crawl around sub-Antarctic seafloor

Next Article

Astro-Challenge: Following Venus From Dusk Til Dawn

Related Posts

Pfizer hires Novartis oncology exec to steer its cancer ambitions

Pfizer hires Novartis oncology exec to steer its cancer...

Feb 9, 2025  0

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Pfizer wants in on Summit’s goal to beat Keytruda via A...

Feb 24, 2025  0

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

Updated: Lilly joins Trump administration to announce $...

Feb 26, 2025  0